Could a leukemia drug boost prostate cancer treatment?
NCT ID NCT06834321
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This study tests whether adding the drug homoharringtonine to standard hormone therapy before prostate removal surgery can better shrink or eliminate tumors. About 96 men with locally advanced or limited metastatic prostate cancer will receive either the combo or hormone therapy alone before surgery. The goal is to see if the combo leads to fewer cancer cells left behind and longer remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First People Hospital of Nantong City
RECRUITINGNantong, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhongda Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.